Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Internal Medicine | Journal

Back to Journal Articles

LDL Increase on Omega-3 Plus Simvastatin Only in Subgroup

Last Updated: June 04, 2010.

The increase in low-density lipoprotein cholesterol that occurs with the addition of omega-3 treatment to simvastatin appears to happen mainly in those with low baseline -density lipoprotein cholesterol while on simvastatin alone, according to research published in the May 15 issue of the American Journal of Cardiology.

FRIDAY, June 4 (HealthDay News) -- The increase in low-density lipoprotein (LDL) cholesterol that occurs with the addition of omega-3 treatment to simvastatin appears to happen mainly in those with low baseline LDL while on simvastatin alone, according to research published in the May 15 issue of the American Journal of Cardiology.

Kevin C. Maki, Ph.D., of Provident Clinical Research in Glen Ellyn, Ill., and Bloomington, Ind., and colleagues analyzed data from an eight-week trial of 256 participants randomized to prescription omega-3 acid ethyl ester (P-OM3) or placebo plus diet and simvastatin to investigate predictors of LDL cholesterol response to P-OM3 therapy in men and women with mixed lipid disorders during diet plus simvastatin therapy.

The researchers found the baseline LDL cholesterol tertile to be a significant predictor of LDL response. The median LDL cholesterol response in the P-OM3 group was +9.5 percent in the first tertile (<80.4 mg/dL), −0.9 percent in the second tertile, and +6.4 percent in the third tertile (≥99.0 mg/dL). Triglyceride and non-high-density, very-low-density, and high-density lipoprotein cholesterol responses did not change significantly with baseline LDL cholesterol tertile. Over all tertiles of LDL, very-low-density lipoprotein cholesterol was reduced to a larger extent, resulting in a net decrease of cholesterol concentration.

"In conclusion, these results suggest that the increase in LDL cholesterol that occurred with the addition of P-OM3 to simvastatin therapy in subjects with mixed dyslipidemia was confined predominantly to those with low LDL cholesterol levels while receiving simvastatin monotherapy," the authors write.

The trial was funded by a grant from GlaxoSmithKline.

Abstract
Full Text (subscription or payment may be required)


Previous: CDC: Many U.S. Teens Have Abused Prescription Drugs Next: Low HDL Predicts Development of Abdominal Aortic Aneurysm

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: